ChamediTec Launches Entry into China with Filler 'Hiafillia'
[Asia Economy Reporter Cho Hyun-ui] ChamediTech announced on the 18th that it will enter the Chinese market with its hyaluronic acid filler 'Hiafillia.'
ChamediTech plans to complete the Phase 3 clinical trial of Hiafillia in China by August next year and aims to undergo review by the China Food and Drug Administration (CFDA) for product approval in 2022.
Hiafillia is a hyaluronic acid filler developed independently by ChamediTech, and the company explained that it has established its presence in 15 countries including Europe and the Middle East.
At the end of last year, ChamediTech began a Phase 3 clinical trial to evaluate the safety and efficacy of Hiafillia on over 200 Chinese patients with wrinkles on both the nose and lips. The clinical trial is being conducted at four institutions, including Zhejiang Provincial People's Hospital.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- One in 77 Koreans Exposed to Drugs... Enough Money for 6,600 Luxury Gangnam Apartments Circulates in Drug Market [ChwiYakGukga] ⑩
- "Greater Impact on Women Than Men"... The 'Diet Trap' That Causes Sleepless Nights and Suffering
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
Kim Seok-jin, CEO of ChamediTech, said, "China is a market expected to experience high growth due to the relatively low supply compared to the demand for fillers," adding, "Based on overseas experience and clinical data, we will ensure that Hiafillia successfully enters the Chinese market."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
